TriSTAR0702

TriSTAR0702 is a trispecific antibody being developed by Marengo Therapeutics as part of their proprietary TriSTAR (Trispecific Precision T Cell Engager) platform for oncology. The TriSTAR platform is designed to redirect and expand memory Vβ T cells directly to tumors, particularly targeting antigen-low or 'cold' tumors with superior anti-tumor activity. TriSTAR0702 is a partnered program in Marengo's pipeline, though the specific tumor antigen targets and detailed mechanism of action have not been publicly disclosed. The TriSTAR platform represents Marengo's next-generation precision T cell engager technology, building on their approach of targeting germline-encoded variable beta (Vβ) regions of the T cell receptor to selectively modulate T cell subsets for cancer treatment.